Adaptimmune Therapeutics-ADRADAPY
13F holders, Q4 2025 (December 31)10holders −45
1new positions
46sold out
$0.05avg. 13F price*
At the end of Q4 2025, 10 institutions reported holding Adaptimmune Therapeutics-ADR (ADAPY) in their 13F filings, down 45 from Q3 2025. 1 opened new positions and 46 sold out. The largest holders were Josh Arnold Investment Consultant, LLC ($38K), Empirical Finance, LLC ($21K) and Rathbones Group PLC ($11K).
- Company
- Adaptimmune Therapeutics-ADR
- CUSIP
- 00653A107
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $38K |
| Exits | 46 | $5.1M |
All 13F filers, Q3 2025 → Q4 2025: 277,521 shares bought and 40,719,890 shares sold, net −40,442,369 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Josh Arnold Investment Consultant, LLC | 0.03% | New | 20,000 | $38K |
| Empirical Finance, LLC | 0.00% | No change | 800,000 | $21K |
| Rathbones Group PLC | 0.00% | No change | 432,818 | $11K |
| XTX Topco Ltd | 0.00% | Add +245.2% | 353,836 | $9K |
| Simplex Trading, LLC | 0.00% | Add +49.8% | 18,610 | $483 |
| Rhumbline Advisers | 0.00% | Reduce -36.3% | 3,661 | $95 |
| Barclays PLC | 0.00% | Reduce -0.1% | 2,532 | $66 |
| Acadian Asset Management LLC | 0.00% | Reduce -98.8% | 17,167 | $0 |
| X-Square Capital, LLC | 0.00% | Reduce -1.9% | 11,359 | $0 |
| TD Waterhouse Canada Inc. | 0.00% | No change | 14 | $0 |
"% of holder's portfolio" is ADAPY's weight in each manager's 13F, not the share of Adaptimmune Therapeutics-ADR the manager owns.